Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 3Phase 2/3 2Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 146Leukemia 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Congenital Abnormalities 30Myelodysplastic Syndromes 25Leukemia, Monocytic, Acute 23Recurrence 22Leukemia, Myelomonocytic, Acute 22Leukemia, Erythroblastic, Acute 20Leukemia, Megakaryoblastic, Acute 19Lymphoma 17Leukemia, Biphenotypic, Acute 13Lymphoma, Non-Hodgkin 12Burkitt Lymphoma 12Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 11Blast Crisis 11Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Follicular 8Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Eosinophilic, Acute 7Leukemia, Basophilic, Acute 7Myeloproliferative Disorders 6Lymphoma, B-Cell, Marginal Zone 6Hodgkin Disease 6Hematologic Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Leukemia, Promyelocytic, Acute 5Leukemia, Myeloid, Accelerated Phase 5

Interventions

Cyclophosphamide 7fludarabine phosphate 6fludarabine 5Immunotherapy, Adoptive 3blinatumomab 2Cytarabine 2Azacitidine 2AP 1903 reagent 2venetoclax 1tisagenlecleucel 1ruxolitinib 1relugolix 1pulrodemstat besilate 1niraparib 1nilotinib 1enzalutamide 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Rituximab 1Radiotherapy 1NKTR-255 1Melphalan 1Injections 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Cetuximab 1CTL019 chimeric antigen receptor 1CD3 Complex 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm, Residual × Cytarabine × Clear all
NCT05987696 2026-02-11

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Completed
2 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05601830 2024-11-06

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Terminated
1 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡